Abstract
Tamoxifen has played a vital role in endocrine therapy for the treatment of estrogen receptor–positive breast cancer. We examined the effect of tamoxifen in patients with a thin endometrium in frozen–thawed embryo transfer (FET) cycles and compared the improvement in endometrial thickness (EMT) and pregnancy outcomes stratified by different etiologies of thin endometrium. A total of 226 women were recruited for a new tamoxifen protocol; all had an EMT of less than 7.5 mm in previous cycles, including natural cycle (NC), hormone replacement treatment (HRT), and ovulation induction (OI) cycles. Compared with previous cycles, tamoxifen cycles showed a significantly increased EMT (from 6.11 ± 0.98 mm to 7.87 ± 1.48 mm in the NC group, from 6.24 ± 1.01 mm to 8.22 ± 1.67 mm in the HRT group, and from 6.34 ± 1.03 mm to 8.05 ± 1.58 mm in the OI group; all P <.001). Patients were further divided into 3 groups based on the causes of their thin endometrium: (1) history of intrauterine adhesion (n = 34), (2) history of uterine curettage (n = 141), and (3) polycystic ovary syndrome (PCOS; n ¼ 51). Patients with PCOS obtained the thickest EMT (9.31±1.55 mm), the lowest cycle cancellation rate (11.76%), and the highest rate of clinical pregnancy (60%) and live birth (55.56%) per transfer (P <.001). Multivariable regression analysis showed that EMT was related to live birth (odds ratio: 1.487; 95% confidence interval: 1.172-1.887). A tamoxifen protocol improves EMT in patients after NC, HRT, and OI cycles during FET. Patients with PCOS show the most benefit from tamoxifen and achieve better pregnancy outcomes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Paulson RJ, Sauer MV, Lobo RA. Embryo implantation after human in vitro fertilization: importance of endometrial receptivity. Fertil Steril. 1990;53(5):870–874.
Jarvela IY, Sladkevicius P, Kelly S, Ojha K, Campbell S, Nargund G. Evaluation of endometrial receptivity during in-vitro fertilization using three-dimensional power Doppler ultrasound. Ultrasound Obstet Gynecol. 2005;26(7):765–769.
El-Toukhy T, Coomarasamy A, Khairy M, et al. The relationship between endometrial thickness and outcome of medicated frozen embryo replacement cycles. Fertil Steril. 2008;89(4):832–839.
Chen MJ, Yang JH, Peng FH, Chen SU, Ho HN, Yang YS. Extended estrogen administration for women with thin endometrium in frozen-thawed in-vitro fertilization programs. J Assist Reprod Genet. 2006;23(7-8):337–342.
Gleicher N, Vidali A, Barad DH. Successful treatment of unresponsive thin endometrium. Fertil Steril. 2011;95(6):2113–2123.
Gargett CE, Healy DL. Generating receptive endometrium in Asherman’s syndrome. J Hum Reprod Sci. 2011;4(1):49–52.
Weckstein LN, Jacobson A, Galen D, Hampton K, Hammel J. Low-dose aspirin for oocyte donation recipients with a thin endometrium: prospective, randomized study. Fertil Steril. 1997; 68(5):927–930.
Acharya S, Yasmin E, Balen AH. The use of a combination of pentoxifylline and tocopherol in women with a thin endometrium undergoing assisted conception therapies—a report of 20 cases. Hum Fertil (Camb). 2009;12(4):198–203.
Ledee-Bataille N, Olivennes F, Lefaix JL, Chaouat G, Frydman R, Delanian S. Combined treatment by pentoxifylline and tocopherol for recipient women with a thin endometrium enrolled in an oocyte donation programme. Hum Reprod. 2002;17(5): 1249–1253.
Takasaki A, Tamura H, Miwa I, Taketani T, Shimamura K, Sugino N. Endometrial growth and uterine blood flow: a pilot study for improving endometrial thickness in the patients with a thin endometrium. Fertil Steril. 2010;93(6):1851–1858.
Pourmatroud E, Zargar M, Nikbakht R, Moramazi F. A new look at tamoxifen: co-administration with letrozole in intrauterine insemination cycles. Arch Gynecol Obstet. 2013;287(2): 383–387.
LE Donne M, Alibrandi A, Ciancimino L, Azzerboni A, Chiofalo B, Triolo O. Endometrial pathology in breast cancer patients: effect of different treatments on ultrasonographic, hysteroscopic and histological findings. Oncol Lett. 2013;5(4): 1305–1310.
Reynolds K, Khoury J, Sosnowski J, Thie J, Hofmann G. Comparison of the effect of tamoxifen on endometrial thickness in women with thin endometrium (<7 mm) undergoing ovulation induction with clomiphene citrate. Fertil Steril. 2010;93(6): 2091–2093.
Wang CW, Horng SG, Chen CK, et al. Ovulation induction with tamoxifen and alternate-day gonadotrophin in patients with thin endometrium. Reprod Biomed Online. 2008;17(1):20–26.
Seyedoshohadaei F, Zandvakily F, Shahgeibi S. Comparison of the effectiveness of clomiphene citrate, tamoxifen and letrozole in ovulation induction in infertility due to isolated unovulation. Iran J Reprod Med. 2012;10(6):531–536.
Chen X, Chen S. Successful pregnancy in recurrent thin endometrium with new uses for an old drug. J IVF Reprod Med Genet. 2013;1(110): Doi:10.4172/jfiv.1000110.
Tian X, Chen X, Xu L, et al. Effect of tamoxifen on clinical outcome of patients with thin endometrium undergoing frozenthawed embryo transfer. Chin J Pract Gynecol Obstetr. 2015; 31(9):736–740.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
Chen Z, Zhang Y, Liu J, et al. China diagnosis criteria of polycystic ovarian syndrome diagnosis [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2012;47(47):74–75.
Senturk LM, Erel CT. Thin endometrium in assisted reproductive technology. Curr Opin Obstet Gynecol. 2008;20(3):221–228.
Mahajan N, Sharma S. The endometrium in assisted reproductive technology: how thin is thin? J Hum Reprod Sci. 2016;9(1):3–8.
Kasius A, Smit JG, Torrance HL, et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(4):530–541.
Saadat M, Truong PT, Kader HA, et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer Am Cancer Soc. 2007;110(1):31–37.
Lasset C, Bonadona V, Mignotte H, Brémond A. Tamoxifen and risk of endometrial cancer. Lancet. 2001;357(9249):66–67.
Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). Oncol Lett. 2015;9(4):1495–1501.
Lin SL, Yan LY, Zhang XT, et al. ER-alpha36, a variant of ERalpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLos One. 2010;5(2):e9013.
Williams-Brown MY, Salih SM, Xu X, et al. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol. 2011;126(3-5):78–86.
Kommoss F, Karck U, Prompeler H, Pfisterer J, Kirkpatrick CJ. Steroid receptor expression in endometria from women treated with tamoxifen. Gynecol Oncol. 1998;70(2):188–191.
Mourits MJ, Ten HK, van der Zee AG, Willemse PH, de Vries EG, Hollema H. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol. 2002;55(7):514–519.
Elkas J, Armstrong A, Pohl J, Cuttitta F, Marti´nez A, Gray K. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen. Obstet Gynecol. 2000;95(5):697–703.
Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002;295(5564):2465–2468.
Fong CJ, Burgoon LD, Williams KJ, Forgacs AL, Zacharewski TR. Comparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mice. BMC Genomics. 2007;8:151.
Zhang H, McElrath T, Tong W, Pollard JW. The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation. J Endocrinol. 2005;184(1):129–140.
Mourits MJ, Hollema H, De Vries EG, Ten Hoor KA, Willemse PH, Van Der Zee AG. Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol. 2002;33(3):341–346.
Cooke PS, Buchanan DL, Young P, et al. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci U S A. 1997;94(12):6535–6540.
Giudice LC. Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab. 2006;20(2):235–244.
Shang K, Jia X, Qiao J, Kang J, Guan Y. Endometrial abnormality in women with polycystic ovary syndrome. Reprod Sci. 2012; 19(7):674–683.
Indhavivadhana S. Hyperandrogenemia is associated with thin endometrium in reproductive-aged Thai women with polycystic ovary syndrome. Asian Biomed. 2013;7(4):545–551.
Das B, Gupta K, Gulati G. Thin endometrium: a challenge in infertility management. Aogo Bulletin. 2015;15(2):12–15.
Hulchiy M, Nybacka A, Sahlin L, Hirschberg AL. Endometrial expression of estrogen receptors and the androgen receptor in women with polycystic ovary syndrome: a lifestyle intervention study. J Clin Endocrinol Metab. 2016;101(2):561–571.
Shufaro Y, Simon A, Laufer N, Fatum M. Thin unresponsive endometrium—a possible complication of surgical curettage compromising ART outcome. J Assist Reprod Genet. 2008; 25(8):421–425.
Deans R, Abbott J. Review of intrauterine adhesions. J Minim Invasive Gynecol. 2010;17(5):555–569.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ke, H., Jiang, J., Xia, M. et al. The Effect of Tamoxifen on Thin Endometrium in Patients Undergoing Frozen—Thawed Embryo Transfer. Reprod. Sci. 25, 861–866 (2018). https://doi.org/10.1177/1933719117698580
Published:
Issue Date:
DOI: https://doi.org/10.1177/1933719117698580